CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING

Described herein are crystalline forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3- dihydro-1H-indene-2-carboxylic acid and methods of makingthe same. Such forms of 2-(4- methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid are useful in the preparation of pharma...

Full description

Saved in:
Bibliographic Details
Main Authors ROCCO, WILLIAM, PERNERSTORFER, JOSEF, BRITTAIN, JASON
Format Patent
LanguageEnglish
French
Published 03.03.2022
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Described herein are crystalline forms of 2-(4-methoxy-3-(3-methylphenethoxy)benzamido)-2,3- dihydro-1H-indene-2-carboxylic acid and methods of makingthe same. Such forms of 2-(4- methoxy-3-(3-methylphenethoxy)benzamido)-2,3-dihydro-1H-indene-2-carboxylic acid are useful in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with an EDG-2 receptor antagonist compound. L'invention concerne des formes cristallines d'acide 2-(4-méthoxy-3-(3-méthylphénéthoxy)benzamido)-2,3-dihydro-1H-indène-2-carboxylique et des procédés de préparation associés. Ces formes d'acide 2-(4-méthoxy-3-(3-méthylphénéthoxy)benzamido)-2,3-dihydro-1H-indène-2-carboxylique sont utiles dans la préparation de compositions pharmaceutiques pour le traitement de maladies ou d'états qui tireraient avantage de l'administration d'un composé antagoniste du récepteur EDG-2.
Bibliography:Application Number: CA20213189817